S&P 500   5,125.12 (+0.57%)
DOW   39,068.10 (+0.18%)
QQQ   443.67 (+1.06%)
AAPL   177.67 (-1.70%)
MSFT   412.93 (-0.17%)
META   499.76 (+1.96%)
GOOGL   137.95 (-0.37%)
AMZN   177.93 (+0.66%)
TSLA   201.93 (+0.02%)
NVDA   817.70 (+3.36%)
NIO   5.84 (+1.57%)
AMD   200.35 (+4.06%)
BABA   74.80 (+1.04%)
T   16.99 (+0.35%)
F   12.48 (+0.32%)
MU   95.47 (+5.36%)
CGC   3.27 (-0.61%)
GE   159.23 (+1.49%)
DIS   111.79 (+0.19%)
AMC   4.46 (+3.24%)
PFE   26.61 (+0.19%)
PYPL   60.56 (+0.36%)
XOM   106.10 (+1.51%)
S&P 500   5,125.12 (+0.57%)
DOW   39,068.10 (+0.18%)
QQQ   443.67 (+1.06%)
AAPL   177.67 (-1.70%)
MSFT   412.93 (-0.17%)
META   499.76 (+1.96%)
GOOGL   137.95 (-0.37%)
AMZN   177.93 (+0.66%)
TSLA   201.93 (+0.02%)
NVDA   817.70 (+3.36%)
NIO   5.84 (+1.57%)
AMD   200.35 (+4.06%)
BABA   74.80 (+1.04%)
T   16.99 (+0.35%)
F   12.48 (+0.32%)
MU   95.47 (+5.36%)
CGC   3.27 (-0.61%)
GE   159.23 (+1.49%)
DIS   111.79 (+0.19%)
AMC   4.46 (+3.24%)
PFE   26.61 (+0.19%)
PYPL   60.56 (+0.36%)
XOM   106.10 (+1.51%)
S&P 500   5,125.12 (+0.57%)
DOW   39,068.10 (+0.18%)
QQQ   443.67 (+1.06%)
AAPL   177.67 (-1.70%)
MSFT   412.93 (-0.17%)
META   499.76 (+1.96%)
GOOGL   137.95 (-0.37%)
AMZN   177.93 (+0.66%)
TSLA   201.93 (+0.02%)
NVDA   817.70 (+3.36%)
NIO   5.84 (+1.57%)
AMD   200.35 (+4.06%)
BABA   74.80 (+1.04%)
T   16.99 (+0.35%)
F   12.48 (+0.32%)
MU   95.47 (+5.36%)
CGC   3.27 (-0.61%)
GE   159.23 (+1.49%)
DIS   111.79 (+0.19%)
AMC   4.46 (+3.24%)
PFE   26.61 (+0.19%)
PYPL   60.56 (+0.36%)
XOM   106.10 (+1.51%)
S&P 500   5,125.12 (+0.57%)
DOW   39,068.10 (+0.18%)
QQQ   443.67 (+1.06%)
AAPL   177.67 (-1.70%)
MSFT   412.93 (-0.17%)
META   499.76 (+1.96%)
GOOGL   137.95 (-0.37%)
AMZN   177.93 (+0.66%)
TSLA   201.93 (+0.02%)
NVDA   817.70 (+3.36%)
NIO   5.84 (+1.57%)
AMD   200.35 (+4.06%)
BABA   74.80 (+1.04%)
T   16.99 (+0.35%)
F   12.48 (+0.32%)
MU   95.47 (+5.36%)
CGC   3.27 (-0.61%)
GE   159.23 (+1.49%)
DIS   111.79 (+0.19%)
AMC   4.46 (+3.24%)
PFE   26.61 (+0.19%)
PYPL   60.56 (+0.36%)
XOM   106.10 (+1.51%)

Revolution Medicines (RVMD) Stock Price, News & Analysis

$30.04
+0.56 (+1.90%)
(As of 12:28 PM ET)
Today's Range
$29.54
$30.74
50-Day Range
$26.56
$30.62
52-Week Range
$15.44
$35.60
Volume
339,042 shs
Average Volume
1.19 million shs
Market Capitalization
$3.29 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.80

Revolution Medicines MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
30.0% Upside
$38.33 Price Target
Short Interest
Bearish
15.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.81
Upright™ Environmental Score
News Sentiment
0.29mentions of Revolution Medicines in the last 14 days
Based on 30 Articles This Week
Insider Trading
Selling Shares
$1.60 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.31) to ($3.30) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.51 out of 5 stars

Medical Sector

318th out of 957 stocks

Biological Products, Except Diagnostic Industry

48th out of 160 stocks


RVMD stock logo

About Revolution Medicines Stock (NASDAQ:RVMD)

Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

RVMD Stock Price History

RVMD Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Revolution Medicines, Inc. (RVMD)
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Q4 2023 Revolution Medicines Inc Earnings Call
TD Cowen Sticks to Their Buy Rating for Revolution Medicines (RVMD)
RVMD Mar 2024 33.000 call
RVMD Mar 2024 22.500 put
RVMD Jun 2024 12.500 put
RVMD Sep 2024 19.000 put
Revolution Medicines Inc (RVMD)
Revolution Medicines Is Hard To Understand
See More Headlines
Receive RVMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/26/2024
Today
3/01/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:RVMD
Fax
N/A
Employees
338
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$38.33
High Stock Price Target
$47.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+24.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
9 Analysts

Profitability

Net Income
$-248,710,000.00
Net Margins
-1,003.36%
Pretax Margin
-3,798.71%

Debt

Sales & Book Value

Annual Sales
$11.58 million
Book Value
$16.67 per share

Miscellaneous

Free Float
100,252,000
Market Cap
$3.23 billion
Optionable
Optionable
Beta
1.54
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives















RVMD Stock Analysis - Frequently Asked Questions

Should I buy or sell Revolution Medicines stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RVMD shares.
View RVMD analyst ratings
or view top-rated stocks.

What is Revolution Medicines' stock price target for 2024?

9 brokerages have issued 1-year price objectives for Revolution Medicines' shares. Their RVMD share price targets range from $28.00 to $47.00. On average, they expect the company's stock price to reach $38.33 in the next twelve months. This suggests a possible upside of 30.0% from the stock's current price.
View analysts price targets for RVMD
or view top-rated stocks among Wall Street analysts.

How have RVMD shares performed in 2024?

Revolution Medicines' stock was trading at $28.68 at the start of the year. Since then, RVMD stock has increased by 2.8% and is now trading at $29.48.
View the best growth stocks for 2024 here
.

When is Revolution Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our RVMD earnings forecast
.

How were Revolution Medicines' earnings last quarter?

Revolution Medicines, Inc. (NASDAQ:RVMD) issued its quarterly earnings results on Monday, February, 26th. The company reported ($1.14) EPS for the quarter, missing analysts' consensus estimates of ($0.85) by $0.29. The firm had revenue of $0.74 million for the quarter, compared to analyst estimates of $1.20 million. Revolution Medicines had a negative net margin of 1,003.36% and a negative trailing twelve-month return on equity of 38.39%. The company's quarterly revenue was down 95.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.63) earnings per share.

What other stocks do shareholders of Revolution Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revolution Medicines investors own include Alector (ALEC), Editas Medicine (EDIT), Homology Medicines (FIXX), Gossamer Bio (GOSS), Livongo Health (LVGO), Sorrento Therapeutics (SRNE), Black Diamond Therapeutics (BDTX), Beam Therapeutics (BEAM), CrowdStrike (CRWD) and Precision BioSciences (DTIL).

When did Revolution Medicines IPO?

(RVMD) raised $150 million in an IPO on Thursday, February 13th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO.

Who are Revolution Medicines' major shareholders?

Revolution Medicines' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (13.36%), Nextech Invest Ltd. (5.75%), BVF Inc. IL (5.46%), Bellevue Group AG (4.65%), Price T Rowe Associates Inc. MD (4.23%) and Price T Rowe Associates Inc. MD (4.23%). Insiders that own company stock include Anthony W Boor, Barbara Weber, Jack Anders, Jeanna Steele, Jeff Cislini, Lorence H Kim, Margaret A Horn, Mark A Goldsmith, Peter Svennilson, Rock Ventures Ii LP Third, Rock Ventures Iii LP Third, Stephen Michael Kelsey, Thilo Schroeder, Vincent A Miller and Xiaolin Wang.
View institutional ownership trends
.

How do I buy shares of Revolution Medicines?

Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RVMD) was last updated on 3/1/2024 by MarketBeat.com Staff